Galactosyl prodrug of palmitoylethanolamide: synthesis, stability, cell permeation and cytoprotective activity.
Eur J Pharm Sci
; 62: 33-9, 2014 Oct 01.
Article
em En
| MEDLINE
| ID: mdl-24854456
ABSTRACT
N-Palmitoylethanolamide (PEA) is emerging as a novel therapeutic agent in the treatment of neuropathic pain and neurodegenerative diseases. Unfortunately, PEA poorly reaches the central nervous system (CNS), after peripheral administration, since it is inactivated through intracellular hydrolysis by lipid amidases. Since prodrug approach is one of the most popular methods used to increase cell permeability, the aim of this paper consists in the synthesis of a new galactosyl prodrug of PEA, the palmitoylethanolamide-succinamyl-D-galactos-6'-yl ester (PEAGAL). Biological experiments both in neuroblastoma and in C6 glioma cells, together with quantitative analyses performed through a LC-MS-MS technique, demonstrate the better efficacy of PEAGAL compared to PEA and its higher cell permeation. Our results encourage further experiments in animal models of neuropathic pain and of neurological disorders and/or neurodegenerative diseases, in order to promote a more effective peripherally administrated derivative of PEA.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Palmitatos
/
Pró-Fármacos
/
Fármacos Neuroprotetores
/
Galactose
/
Analgésicos
Idioma:
En
Ano de publicação:
2014
Tipo de documento:
Article